JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB256950

Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

IFNAR1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon1 and Insertion of the selection cassette in exon1.

View Alternative Names

AVP, Alpha type antiviral protein, Antiviral protein, alpha-type, Antiviral protein, beta-type, Beta type antiviral protein, CRF2-1, Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1, IFN Interferon-beta receptor, IFN alpha REC, IFN alpha receptor, IFN alpha/beta Receptor alpha, IFN beta receptor, IFN-R-1, IFN-alpha/beta receptor 1, IFNAR, IFNBR, IFRC, INAR1_HUMAN, Ifnar1, Interferon (alpha beta and omega) receptor 1, Interferon alpha/beta receptor 1, Interferon alpha/beta receptor alpha chain, Interferon beta receptor 1, Interferon-alpha receptor, Type I interferon receptor 1, interferon alpha and beta receptor subunit 1, interferon receptor 1

2 Images
Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate (AB256950)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate (AB256950)

Allele-2 : Insertion of the selection cassette in exon1

Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate (AB256950)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate (AB256950)

Allele-1 : 7 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon1 and Insertion of the selection cassette in exon1.

Disease

Adenocarcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab256950-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human IFNAR1 knockout HeLa cell lysate", "number":"AB256950-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB256950-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
IFNAR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Interferon alpha/beta receptor 1 also known as IFNAR1 is an important component of the interferon receptor complex which includes the interferon beta receptor (IFNBR) and the broader class of interferon receptors. IFNAR1 is a transmembrane protein with a molecular mass of approximately 100 kDa. It shows expression in various tissues but predominantly in cells of the immune system. This expression pattern enables IFNAR1 to play a central role in mediating responses to interferon alpha and beta which are cytokines important in the immune response.
Biological function summary

IFNAR1 partners with interferon alpha receptor 2 (IFNAR2) to form a functional receptor complex. This complex binds interferons alpha and beta triggering signal transduction cascades vital for antiviral defense. Through this interaction IFNAR1 facilitates cellular immune responses including the activation of antiviral genes and modulation of cell proliferation. IFNAR1's role extends beyond immediate immune response influencing processes like cell differentiation and apoptosis.

Pathways

IFNAR1 is a participant in the JAK-STAT signaling pathway a significant pathway for transmitting cytokine signals. Upon interferon binding it activates the associated Janus kinases (JAKs) which in turn phosphorylate signal transducers and activators of transcription (STATs) specifically STAT1 and STAT2. This chain of events results in the transcription of interferon-stimulated genes that provide antiviral defenses and promote immune regulation. IFNAR1's engagement in these pathways makes it an integral part of immune system communication.

IFNAR1 associates strongly with autoimmune diseases and viral infections. In lupus an autoimmune disorder dysregulation in interferon signaling involving IFNAR1 contributes to disease progression. Moreover in viral infections like hepatitis C the response of IFNAR1 to interferon therapies can influence treatment outcomes. Understanding these connections facilitates therapeutic strategies that target interferon pathways for improved disease management.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Cell Lines & Lysates

AB261782

Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line

Western blot - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (AB261782)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB124764

Anti-Interferon alpha/beta receptor 1 antibody [EPR6244]

RabMAb|Recombinant|KO Validated

Western blot - Anti-Interferon alpha/beta receptor 1 antibody [EPR6244] (AB124764)

  • 5
  • 2
Primary Antibodies

AB92381

Anti-IL-2 antibody [EPR2780]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-IL-2 antibody [EPR2780] (AB92381)

  • 5
  • 2

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com